German B, Alaiwi S, Ho K, Nanda J, Fonseca M, Burkhart D
Cancer Res Commun. 2024; 4(9):2295-2307.
PMID: 39113611
PMC: 11368174.
DOI: 10.1158/2767-9764.CRC-24-0069.
Krushkal J, Vural S, Jensen T, Wright G, Zhao Y
Clin Epigenetics. 2022; 14(1):161.
PMID: 36461044
PMC: 9716673.
DOI: 10.1186/s13148-022-01368-7.
Huang C, Han W, Wu Y, Shen G
Front Genet. 2022; 13:817656.
PMID: 35991567
PMC: 9387026.
DOI: 10.3389/fgene.2022.817656.
Wei M, Yang R, Ye M, Zhan Y, Liu B, Meng L
Am J Cancer Res. 2022; 12(5):1960-1981.
PMID: 35693071
PMC: 9185624.
Liu J, Xu J, Luo B, Tang J, Hou Z, Zhu Z
Cancers (Basel). 2022; 14(6).
PMID: 35326741
PMC: 8946480.
DOI: 10.3390/cancers14061590.
MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.
Jiao M, Zhang F, Teng W, Zhou C
Int J Gen Med. 2022; 15:3003-3030.
PMID: 35313552
PMC: 8934167.
DOI: 10.2147/IJGM.S351638.
Significant Biomarkers Identification Associated with Cutaneous Squamous Cell Carcinoma Progression.
Qiu C, Shen B, Sun X
Int J Gen Med. 2022; 15:2347-2360.
PMID: 35264873
PMC: 8901050.
DOI: 10.2147/IJGM.S357022.
ZNF217: the cerberus who fails to guard the gateway to lethal malignancy.
Li Y, Wu H, Wang Q, Xu S
Am J Cancer Res. 2021; 11(7):3378-3405.
PMID: 34354851
PMC: 8332857.
MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q, Wang M, Hu Y, Zhao E, Li J, Ren L
Theranostics. 2021; 11(12):5794-5812.
PMID: 33897882
PMC: 8058714.
DOI: 10.7150/thno.56604.
Association between B- proto-oncogene and the development of malignant tumors.
Jin Y, Qi G, Chen G, Wang C, Fan X
Oncol Lett. 2021; 21(2):166.
PMID: 33552284
PMC: 7798104.
DOI: 10.3892/ol.2021.12427.
Function and Regulation of Nuclear DNA Sensors During Viral Infection and Tumorigenesis.
Zhang F, Yuan Y, Ma F
Front Immunol. 2021; 11:624556.
PMID: 33505405
PMC: 7829187.
DOI: 10.3389/fimmu.2020.624556.
RBM38 in cancer: role and mechanism.
Zou C, Wan Y, He L, Zheng J, Mei Y, Shi J
Cell Mol Life Sci. 2020; 78(1):117-128.
PMID: 32642788
PMC: 11072576.
DOI: 10.1007/s00018-020-03593-w.
Aurora A inhibition limits centrosome clustering and promotes mitotic catastrophe in cells with supernumerary centrosomes.
Navarro-Serer B, Childers E, Hermance N, Mercadante D, Manning A
Oncotarget. 2019; 10(17):1649-1659.
PMID: 30899434
PMC: 6422193.
DOI: 10.18632/oncotarget.26714.
Therapeutic modulation of RNA-binding protein Rbm38 facilitates re-endothelialization after arterial injury.
Sonnenschein K, Fiedler J, Pfanne A, Just A, Mitzka S, Geffers R
Cardiovasc Res. 2019; 115(12):1804-1810.
PMID: 30843048
PMC: 6755352.
DOI: 10.1093/cvr/cvz063.
Prognostic implications of MYBL2 in resected Chinese gastric adenocarcinoma patients.
Jia Y, Gao Y, Li J, Chang Z, Yan J, Qin Y
Onco Targets Ther. 2019; 12:1129-1135.
PMID: 30809094
PMC: 6376880.
DOI: 10.2147/OTT.S188820.
B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3.
Fan X, Wang Y, Jiang T, Cai W, Jin Y, Niu Y
Int J Mol Sci. 2018; 19(5).
PMID: 29772705
PMC: 5983693.
DOI: 10.3390/ijms19051479.
ZNF280B promotes the growth of gastric cancer and .
Zhai J, Yang Z, Cai X, Yao G, An Y, Wang W
Oncol Lett. 2018; 15(4):5819-5824.
PMID: 29556309
PMC: 5844094.
DOI: 10.3892/ol.2018.8060.
ARD1-mediated aurora kinase A acetylation promotes cell proliferation and migration.
Thuy Lu Vo T, Park J, Seo J, Lee E, Choi H, Bae S
Oncotarget. 2017; 8(34):57216-57230.
PMID: 28915666
PMC: 5593637.
DOI: 10.18632/oncotarget.19332.
MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis.
Musa J, Aynaud M, Mirabeau O, Delattre O, Grunewald T
Cell Death Dis. 2017; 8(6):e2895.
PMID: 28640249
PMC: 5520903.
DOI: 10.1038/cddis.2017.244.
B-Myb Is Up-Regulated and Promotes Cell Growth and Motility in Non-Small Cell Lung Cancer.
Jin Y, Zhu H, Cai W, Fan X, Wang Y, Niu Y
Int J Mol Sci. 2017; 18(6).
PMID: 28555007
PMC: 5485926.
DOI: 10.3390/ijms18060860.